Skip to main content
. 2021 Dec 9;40(9):945–955. doi: 10.1200/JCO.20.03585

FIG 2.

FIG 2.

(A) OS, (B) EFS, (C) DOR, and (D) DBA outcomes of infused cohort. OS and EFS estimates in all infused, evaluable patients. DOR and DBA estimates in patients who achieved morphologic remission. DBA, duration of B-cell aplasia; DOR, duration of remission; EFS, event-free survival; OS, overall survival.